A detailed history of Bayesian Capital Management, LP transactions in Amgen Inc stock. As of the latest transaction made, Bayesian Capital Management, LP holds 12,022 shares of AMGN stock, worth $3.8 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
12,022
Previous 7,322 64.19%
Holding current value
$3.8 Million
Previous $2.08 Million 80.49%
% of portfolio
0.44%
Previous 0.21%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$262.75 - $319.31 $1.23 Million - $1.5 Million
4,700 Added 64.19%
12,022 $3.76 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $1.97 Million - $2.38 Million
7,322 New
7,322 $2.08 Million
Q3 2023

Nov 14, 2023

SELL
$218.65 - $271.46 $437,300 - $542,920
-2,000 Reduced 10.87%
16,400 $4.41 Million
Q2 2023

Aug 14, 2023

BUY
$214.27 - $253.37 $2.89 Million - $3.42 Million
13,500 Added 275.51%
18,400 $4.09 Million
Q1 2023

May 15, 2023

BUY
$225.79 - $275.2 $1.11 Million - $1.35 Million
4,900 New
4,900 $1.18 Million
Q2 2022

Aug 15, 2022

SELL
$230.71 - $256.74 $992,053 - $1.1 Million
-4,300 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$219.27 - $242.57 $942,861 - $1.04 Million
4,300 New
4,300 $1.04 Million
Q1 2020

May 15, 2020

SELL
$182.24 - $241.7 $160,371 - $212,696
-880 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$189.21 - $243.2 $166,504 - $214,016
880 New
880 $212,000
Q1 2019

May 14, 2019

SELL
$180.87 - $203.88 $1.79 Million - $2.02 Million
-9,900 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$178.4 - $208.25 $1.77 Million - $2.06 Million
9,900 New
9,900 $1.93 Million
Q2 2018

Aug 14, 2018

SELL
$166.05 - $186.51 $1.73 Million - $1.94 Million
-10,400 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$169.43 - $198.0 $1.76 Million - $2.06 Million
10,400 New
10,400 $1.77 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.